Acutaas Chemicals Q4 FY26 PAT Surges 114% to ₹1,343 Million
Acutaas Chemicals reported a strong Q4 FY26 with revenue up 40.3% to ₹4,328 million and PAT surging 114.1% to ₹1,343 million. For FY26, revenue grew 33.0% to ₹13,394 million and PAT more than doubled to ₹3,564 million. The company is confident of achieving 25% revenue growth in FY27.
The announcement details strong financial performance with substantial growth in key metrics and a positive future outlook, which is highly material for investors and stakeholders.
The company reported significant year-on-year growth in revenue, EBITDA, and PAT for both the fourth quarter and the full fiscal year, along with record PAT margins and a positive outlook for the next fiscal year.
Acutaas Chemicals Limited (formerly Ami Organics Limited) announced its financial results for the fourth quarter and full year ended March 31, 2026, along with an investor presentation.
For the fourth quarter of FY26, the company reported revenue from operations of ₹4,328 million, marking a significant year-on-year increase of 40.3%. EBITDA for the quarter grew by 116.0% to ₹1,835 million, and Profit After Tax (PAT) surged by 114.1% to ₹1,343 million. The PAT margin for the quarter stood at a record 31.0%.
For the full fiscal year FY26, revenue from operations reached ₹13,394 million, an increase of 33.0% compared to FY25. EBITDA for FY26 more than doubled, rising by 107.0% to ₹4,804 million, while PAT grew by 122.2% to ₹3,564 million. The company highlighted strong performance driven by its diversified chemicals business across three high-growth verticals: Battery Chemicals, Semiconductors, and Pharmaceutical CDMO.
Mr. Naresh Patel, Executive Chairman and Managing Director, expressed satisfaction with the strong close to FY26 and confidence in delivering 25% revenue growth in FY27. He emphasized the strategy to de-risk the revenue base and create multiple engines for long-term growth.
What to do with a filing like this
Acutaas Chemicals Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Acutaas Chemicals Limited. Read the original for the full detail.